AVXL buyout：Anavex Life Sciences Corp. (AVXL)
Anavex Life Sciences Corp. (AVXL)
(NASDAQ:AVXL)sharesbutindividualinvestorscontrol59%ofthecompany.KeyInsightsSignificantcontroloverAnavexLifeSciencesbyindividualinvestors ...。其他文章還包含有：「AnavexdirectorThomasSteffenacquires$22.6kin...」、「AnavexLifeSciencesCorp.(NASDAQ」、「AnavexLifeSciencesCorp.StockQuote(U.S.」、「AnavexLifeSciencesCorporationStockholderAlert」、「AVXLLAWSUITALERT」、「AVXLStockholders」、「EFHutto...
查看更多 離開網站
Anavex director Thomas Steffen acquires $22.6k in ...
https://www.investing.com
(NASDAQ:AVXL), purchased 5,000 shares of the company's common stock. The transaction, amounting to $22,599, was executed at a purchase price ...
Anavex Life Sciences Corp. (NASDAQ
https://finance.yahoo.com
The consensus is that breakeven is near. They anticipate the company to incur a final loss in 2024, before generating positive profits of US$80m in 2025.
Anavex Life Sciences Corp. Stock Quote (U.S.
https://www.marketwatch.com
AVXL | Complete Anavex Life Sciences Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.
Anavex Life Sciences Corporation Stockholder Alert
https://www.businesswire.com
Robbins LLP is Investigating Whether Anavex Life Sciences Corp (AVXL) Misled Investors Regarding the Likelihood of Success of its Clinical ...
AVXL LAWSUIT ALERT
https://ktla.com
AVXL LAWSUIT ALERT: The Gross Law Firm Notifies Anavex Life Sciences Corporation Investors of a Class Action Lawsuit and Upcoming Deadline.
AVXL Stockholders
https://www.globenewswire.com
Robbins LLP is Investigating the Allegations that Anavex Life Sciences Corporation (AVXL) Misled Investors Regarding the Likelihood of Success ...
EF Hutton Initiates Coverage of Anavex Life Sciences ...
https://www.nasdaq.com
Fintel reports that on July 22, 2024, EF Hutton initiated coverage of Anavex Life Sciences (NasdaqGS:AVXL) with a Buy recommendation.
HC Wainwright & Co. Reiterates Anavex Life Sciences ...
https://www.nasdaq.com
Fintel reports that on July 20, 2023, HC Wainwright & Co. reiterated coverage of Anavex Life Sciences (NASDAQ:AVXL) with a Buy recommendation.
May 13
https://www.prnewswire.com
ALLEGATIONS: The complaint alleges that on December 2, 2022, AVXL announced positive topline results from its Phase 2b/3 ANAVEX®2-73-AD-004 clinical trial of ...